Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study.

Autor:	Mazzeo S; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Ingannato A; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Giacomucci G; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Manganelli A; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Moschini V; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Balestrini J; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Cavaliere A; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Morinelli C; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Galdo G; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Emiliani F; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Piazzesi D; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy., Crucitti C; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Frigerio D; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Polito C; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Berti V; Department of Biomedical, Experimental and Clinical Sciences 'Mario Serio', University of Florence, Florence, Italy., Bagnoli S; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy., Padiglioni S; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Regional Referral Centre for Relational Criticalities - 50139, Tuscany Region, Italy., Sorbi S; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Nacmias B; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.; IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Bessi V; Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.; Research and Innovation Centre for Dementia-CRIDEM, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Jazyk:	angličtina
Zdroj:	European journal of neurology [Eur J Neurol] 2024 Jan; Vol. 31 (1), pp. e16089. Date of Electronic Publication: 2023 Oct 05.
DOI:	10.1111/ene.16089
Abstrakt:	Background and Purpose: We aimed to evaluate the accuracy of plasma neurofilament light chain (NfL) in predicting Alzheimer's disease (AD) and the progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Methods: This longitudinal cohort study involved 140 patients (45 with SCD, 73 with MCI, and 22 with AD dementia [AD-D]) who underwent plasma NfL and AD biomarker assessments (cerebrospinal fluid, amyloid positron emission tomography [PET], and 18 F-fluorodeoxyglucose-PET) at baseline. The patients were rated according to the amyloid/tau/neurodegeneration (A/T/N) system and followed up for a mean time of 2.72 ± 0.95 years to detect progression from SCD to MCI and from MCI to AD. Forty-eight patients (19 SCD, 29 MCI) also underwent plasma NfL measurements 2 years after baseline. Results: At baseline, plasma NfL detected patients with biomarker profiles consistent with AD (A+/T+/N+ or A+/T+/N-) with high accuracy (area under the curve [AUC] 0.82). We identified cut-off values of 19.45 pg/mL for SCD and 20.45 pg/mL for MCI. During follow-up, nine SCD patients progressed to MCI (progressive SCD [p-SCD]), and 14 MCI patients developed AD dementia (progressive MCI [p-MCI]). The previously identified cut-off values provided good accuracy in identifying p-SCD (80% [95% confidence interval 65.69: 94.31]). The rate of NfL change was higher in p-MCI (3.52 ± 4.06 pg/mL) compared to non-progressive SCD (0.81 ± 1.25 pg/mL) and non-progressive MCI (-0.13 ± 3.24 pg/mL) patients. A rate of change lower than 1.64 pg/mL per year accurately excluded progression from MCI to AD (AUC 0.954). Conclusion: Plasma NfL concentration and change over time may be a reliable, non-invasive tool to detect AD and the progression of cognitive decline at the earliest stages of the disease. (© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text